S&P 500   5,069.76
DOW   38,949.02
QQQ   435.27
Palantir Stock Has It all… Except the Analysts' Support
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
3 wealth-compounding stocks to beat the market this decade
FedEx ends naming rights agreement for the Washington Commanders stadium long known as FedEx Field
Critical asset just had biggest fall on record (Ad)
2 Navigation Stocks That Continue to Defy Gravity
Workday Stock Price is Working on a Buy-the-Dip Opportunity
Critical asset just had biggest fall on record (Ad)
Are NFTs Back? Why NFTs Will Make a Comeback in 2024
Applied Optoelectronics earnings dumper, pain now for gain later?
S&P 500   5,069.76
DOW   38,949.02
QQQ   435.27
Palantir Stock Has It all… Except the Analysts' Support
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
3 wealth-compounding stocks to beat the market this decade
FedEx ends naming rights agreement for the Washington Commanders stadium long known as FedEx Field
Critical asset just had biggest fall on record (Ad)
2 Navigation Stocks That Continue to Defy Gravity
Workday Stock Price is Working on a Buy-the-Dip Opportunity
Critical asset just had biggest fall on record (Ad)
Are NFTs Back? Why NFTs Will Make a Comeback in 2024
Applied Optoelectronics earnings dumper, pain now for gain later?
S&P 500   5,069.76
DOW   38,949.02
QQQ   435.27
Palantir Stock Has It all… Except the Analysts' Support
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
3 wealth-compounding stocks to beat the market this decade
FedEx ends naming rights agreement for the Washington Commanders stadium long known as FedEx Field
Critical asset just had biggest fall on record (Ad)
2 Navigation Stocks That Continue to Defy Gravity
Workday Stock Price is Working on a Buy-the-Dip Opportunity
Critical asset just had biggest fall on record (Ad)
Are NFTs Back? Why NFTs Will Make a Comeback in 2024
Applied Optoelectronics earnings dumper, pain now for gain later?
S&P 500   5,069.76
DOW   38,949.02
QQQ   435.27
Palantir Stock Has It all… Except the Analysts' Support
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
3 wealth-compounding stocks to beat the market this decade
FedEx ends naming rights agreement for the Washington Commanders stadium long known as FedEx Field
Critical asset just had biggest fall on record (Ad)
2 Navigation Stocks That Continue to Defy Gravity
Workday Stock Price is Working on a Buy-the-Dip Opportunity
Critical asset just had biggest fall on record (Ad)
Are NFTs Back? Why NFTs Will Make a Comeback in 2024
Applied Optoelectronics earnings dumper, pain now for gain later?
NASDAQ:TENX

Tenax Therapeutics (TENX) Stock Price, News & Analysis

$4.14
-0.04 (-0.96%)
(As of 02/28/2024 ET)
Today's Range
$4.03
$4.20
50-Day Range
$3.95
$26.40
52-Week Range
$3.77
$64.40
Volume
49,229 shs
Average Volume
463,354 shs
Market Capitalization
$1.24 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$480.00

Tenax Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
11,494.2% Upside
$480.00 Price Target
Short Interest
Healthy
2.75% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.22mentions of Tenax Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($28.80) to ($6.33) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.22 out of 5 stars


TENX stock logo

About Tenax Therapeutics Stock (NASDAQ:TENX)

Tenax Therapeutics, Inc. develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension. It develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is based in Chapel Hill, North Carolina.

TENX Stock Price History

TENX Stock News Headlines

Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
TENX: First Patient Enrolled
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Why Is Tenax Therapeutics (TENX) Stock Down 64% Today?
TENX: IND Clears Way for Phase III
Why Is Tenax Therapeutics (TENX) Stock Up 300% Today?
Why Tenax Therapeutics (TENX) Stock Is Up 100%
See More Headlines
Receive TENX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tenax Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/16/2021
Today
2/29/2024
Next Earnings (Estimated)
3/04/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:TENX
Employees
7
Year Founded
1967

Price Target and Rating

Average Stock Price Target
$480.00
High Stock Price Target
$480.00
Low Stock Price Target
$480.00
Potential Upside/Downside
+11,494.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-11,050,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$52.12 per share

Miscellaneous

Free Float
292,000
Market Cap
$1.24 million
Optionable
Not Optionable
Beta
2.46

Social Links

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for March 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. Christopher T. Giordano (Age 49)
    CEO, President & Director
    Comp: $563.04k
  • Dr. Stuart Rich M.D. (Age 74)
    Chief Medical Officer & Director
    Comp: $416k
  • Mr. Lawrence R. Hoffman CPA (Age 69)
    Esq., Interim Chief Financial Officer
  • Mr. Doug Randall
    Executive Vice President of Commercial & Business Operations
  • Dr. Douglas Hay
    Senior Vice President of Regulatory Affairs














TENX Stock Analysis - Frequently Asked Questions

Should I buy or sell Tenax Therapeutics stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Tenax Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" TENX shares.
View TENX analyst ratings
or view top-rated stocks.

What is Tenax Therapeutics' stock price target for 2024?

2 Wall Street research analysts have issued 1 year price targets for Tenax Therapeutics' shares. Their TENX share price targets range from $480.00 to $480.00. On average, they predict the company's share price to reach $480.00 in the next twelve months. This suggests a possible upside of 11,494.2% from the stock's current price.
View analysts price targets for TENX
or view top-rated stocks among Wall Street analysts.

How have TENX shares performed in 2024?

Tenax Therapeutics' stock was trading at $21.9680 at the beginning of the year. Since then, TENX stock has decreased by 81.2% and is now trading at $4.14.
View the best growth stocks for 2024 here
.

Are investors shorting Tenax Therapeutics?

Tenax Therapeutics saw a increase in short interest during the month of February. As of February 15th, there was short interest totaling 46,400 shares, an increase of 30.7% from the January 31st total of 35,500 shares. Based on an average daily trading volume, of 288,800 shares, the short-interest ratio is currently 0.2 days. Approximately 2.8% of the company's shares are short sold.
View Tenax Therapeutics' Short Interest
.

When is Tenax Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 4th 2024.
View our TENX earnings forecast
.

How were Tenax Therapeutics' earnings last quarter?

Tenax Therapeutics, Inc. (NASDAQ:TENX) posted its quarterly earnings results on Tuesday, November, 16th. The specialty pharmaceutical company reported ($240.00) earnings per share for the quarter, missing the consensus estimate of ($208.00) by $32.00.

When did Tenax Therapeutics' stock split?

Shares of Tenax Therapeutics reverse split on the morning of Wednesday, January 3rd 2024. The 1-80 reverse split was announced on Wednesday, January 3rd 2024. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, January 3rd 2024. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

What other stocks do shareholders of Tenax Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Tenax Therapeutics investors own include Sorrento Therapeutics (SRNE), AcelRx Pharmaceuticals (ACRX), Inovio Pharmaceuticals (INO), Idera Pharmaceuticals (IDRA), NVIDIA (NVDA), SCYNEXIS (SCYX), Verastem (VSTM), Bank of Hawaii (BOH), Gilead Sciences (GILD) and AVEO Pharmaceuticals (AVEO).

Who are Tenax Therapeutics' major shareholders?

Tenax Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (62.43%) and Concourse Financial Group Securities Inc. (0.00%).
View institutional ownership trends
.

How do I buy shares of Tenax Therapeutics?

Shares of TENX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:TENX) was last updated on 2/29/2024 by MarketBeat.com Staff